What is Visikol?
Visikol operates as a specialized contract research organization (CRO) that provides critical infrastructure for the pharmaceutical and biotechnology industries. The company's core competency lies in its proprietary cell culture assays and advanced tissue imaging techniques, which are designed to accelerate the drug development lifecycle. By acting as an extension of internal R&D teams, Visikol enables its clients to navigate the complexities of preclinical research with greater precision and speed. Their portfolio of services is utilized by the top 20 pharmaceutical companies, reflecting a robust market position and a reputation for technical excellence in high-throughput screening and histological analysis.
How much funding has Visikol raised?
Visikol has raised a total of $725K across 2 funding rounds:
Unspecified
$500K
Grant
$225K
Unspecified (2016): $500K with participation from Foundation Venture Capital Group, LLC
Grant (2016): $225K led by National Science Foundation
Key Investors in Visikol
Foundation Venture Capital Group, LLC
Foundation Venture Capital Group specializes in impact investing by providing pre-seed and seed funding to health-related start-up companies, offering strategic business guidance and operational support.
National Science Foundation
The National Science Foundation is an independent federal agency created by Congress to promote the progress of science and advance national health, prosperity, and welfare.
What's next for Visikol?
With the recent capital injection, Visikol is well-positioned to expand its technological infrastructure and deepen its service offerings. The company is expected to focus on scaling its custom development projects, which serve as a primary revenue driver and a key differentiator in the competitive CRO landscape. As the pharmaceutical industry continues to prioritize efficiency in drug discovery, Visikol's strategic focus on integrating AI-driven imaging with traditional cell culture methods will likely be a central theme in its future growth. The firm is poised to leverage its existing relationships with major research institutions to capture a larger share of the preclinical services market, further solidifying its role as a cornerstone of modern biomedical research.
See full Visikol company page
